Clinical Trials – The Movement Towards Decentralized Clinical Trials

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Decentralized Clinical Trials Market Overview

The decentralized clinical trials market size was 1,291 (trials) in 2021. DCTs also known as virtual trials or direct-to-participant trials, can be defined as clinical trials that use a virtual component to assist with any aspect of the trial itself, including data analysis, data collection, enrollment, and monitoring. DCTs have less necessity in traditional research facilities and data collection structures.

It uses virtual components, such as telemedicine, in-home devices, mobile healthcare, mobile technology, wearable devices, virtual home visits, direct delivery of study drugs and materials to patients’ homes, and other virtual elements to assist with key elements of a clinical trial. The decentralized clinical trials market research report provides a breakdown of DCTs across several clinical trial sectors. The report also highlights the use of DCTs in the industry and against institutional sponsors.

DCT Market Dynamics

The greatest increase in DCT occurred during 2020–2021. DCT usage greatly increased, mainly in 2021, due to increased lockdown measures and global restrictions caused by the COVID-19 pandemic. DCT usage is still relatively high for 2022 and the year is still ongoing. North America dominated both industry and non-industry-sponsored DCTs. DCTs have proven to be cost and time-effective, especially with the use of mobile healthcare, remote patient monitoring, and electronic tracking systems.

DCT Market Segmentation by Regions

Some of the key regions in the DCT market are North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America dominated industry and non-industry DCT trials.

North America is moving toward increased use of DCT trials. Big pharmaceutical sponsors based in the US are looking for new ways to streamline clinical trials, and DCTs have been proven to be effective in doing so.

DCT Market Analysis, by Regions

DCT Market Analysis, by Regions

For more regional insights into the DCT market, download a free report sample

DCT Market Segmentation by Components

Mobile healthcare, telemedicine, wearable devices, web-based technology, and others are the key components in the DCT market. Mobile healthcare was the key virtual component for most trials. Challenges from traditional trial design can be overcome with the use of mobile healthcare.

DCT Market Analysis, by Components

DCT Market Analysis, by Components

For more insights on components into the DCT market, download a free report sample

DCT Market Segmentation by Researched Area

Some of the key researched areas in the DCT market are the central nervous system, metabolic disorders, infectious disease, respiratory, oncology, cardiovascular, and others. The central nervous system is the most researched therapy area for DCT trials.

DCT Market Analysis, by Researched Area

DCT Market Analysis, by Researched Area

For more DCT researched area insights, download a free report sample

DCT Market - Competitive Landscape

Some of the leading companies sponsoring the trials in the decentralized clinical trials market are GlaxoSmithKline (GSK), AstraZeneca, Novartis, Pfizer, Sanofi, and others. Within industry-sponsored trials, GSK has the largest DCT count.

DCT Market Analysis, by Companies

DCT Market Analysis, by Companies

For more insights on companies in the DCT market, download a free report sample

DCT Market Report Overview

Market Size (2021 Trials) 1,291
Key Regions North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America
Key Components Mobile Healthcare, Telemedicine, Wearable Devices, Web-Based Technology, and Others
Key Researched Area Central Nervous System, Metabolic Disorders, Infectious Disease, Respiratory, Oncology, Cardiovascular, and Others
Leading Companies GlaxoSmithKline (GSK), AstraZeneca, Novartis, Pfizer, Sanofi, and Others

Scope

  • Decentralized clinical trials usage is on the rise
  • North America has conducted the most DCTs
  • Mobile Healthcare is the top virtual component used

Reasons to Buy

  • Provides a breakdown of DCTs across several clinical trial sectors.
  • Identifies which areas are using DCTs the most.
  • Highlights the use of DCTs in the industry and against institutional sponsors.

Novartis

GSK

Pfizer

Sanofi

Novo Nordisk

Takeda Pharmaceutical

Boehringer Ingelheim Johnson & Johnson

AstraZeneca

Eli Lilly

Table of Contents

Executive Summary

Introduction

• Report Scope

• Methodology

Clinical Trials Landscape of Real-World Evidence Trials

• 2022 Projected to Be a Leading Year for DCTs

• The Largest Proportion of DCTs Are in Phase II

• Mobile Healthcare Is a Key Virtual Trial Component for DCTs

• North America Leads for DCTs

• North America Dominates for All Virtual Components

• North America leads Single-Country DCTs, Followed by Europe and Asia-Pacific

• US Leads DCT Usage

• Central Nervous System Is the Most Researched Therapy Area for DCTs

• Type 2 Diabetes Is the Most Researched Indication for DCTs

• Low Accrual Rate Is the Leading Cause of Trial Termination

• More Industry Trials Achieve Their Endpoints

• GSK Is the Top Industry Sponsor for DCTs

• Duke University Is the Top Non-Industry Sponsor for DCTs

Key Findings

Appendix

Figures

Figure 1: Number of DCTs by sponsor type and year

Figure 2: DCTs by phase and status

Figure 3: Virtual trial components by status

Figure 4: DCTs by regional distribution

Figure 5: Virtual components by region

Figure 6: Single-country and multinational DCTs by region

Figure 7: Distribution of DCTs by top five countries

Figure 8: DCTs by therapy area

Figure 9: DCTs by indication

Figure 10: Reasons for trial discontinuation of DCTs

Figure 11: Completed trials endpoint status, by sponsor type

Figure 12: Top industry sponsors for DCTs

Figure 13: Top non-industry sponsors for DCTs

Frequently asked questions

Clinical Trials – The Movement Towards Decentralized Clinical Trials thematic reports
Currency USD
$695

Can be used by individual purchaser only

$1,390

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Clinical Trials – The Movement Towards Decentralized Clinical Trials was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clinical Trials – The Movement Towards Decentralized Clinical Trials in real time.

  • Access a live Clinical Trials – The Movement Towards Decentralized Clinical Trials dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.